Lipocine (NASDAQ:LPCN) Stock Price Passes Above Fifty Day Moving Average – Should You Sell?

Lipocine Inc. (NASDAQ:LPCN)’s share price crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $2.97 and traded as high as $3.14. Lipocine shares last traded at $3.11, with a volume of 9,744 shares traded.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research report on Wednesday, October 8th. Alliance Global Partners raised Lipocine to a “strong-buy” rating in a research report on Monday, August 11th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Lipocine in a research report on Wednesday, August 20th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Lipocine Stock Up 0.3%

The stock has a fifty day moving average of $2.97 and a 200-day moving average of $3.14. The stock has a market capitalization of $16.86 million, a price-to-earnings ratio of -3.57 and a beta of 1.29.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.41). The business had revenue of $0.62 million during the quarter, compared to analyst estimates of $1.00 million.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.